Quintiles Transitional Holdings (Q) : The consensus on Quintiles Transitional Holdings (Q) based on 12 analyst recommendation on the company stock is 1.54, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 8 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 3 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Quintiles Transitional Holdings (Q) : Average target price received by Quintiles Transitional Holdings (Q) is $80.35 with an expected standard deviation of $5.06. The most aggressive target on the stock is $87, whereas the most downbeat target is $71. 10 financial analysts are currently covering the stock.
For the current week, the company shares have a recommendation consensus of Buy. Quintiles Transitional Holdings (NYSE:Q): The stock opened at $76.98 on Thursday but the bulls could not build on the opening and the stock topped out at $77.15 for the day. The stock traded down to $76.28 during the day, due to lack of any buying support eventually closed down at $76.75 with a loss of -0.08% for the day. The stock had closed at $76.81 on the previous day. The total traded volume was 1,111,938 shares.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (EVP and COO) of Quintiles Transnational Holdings Inc., Gordon Kevin K had sold 24,000 shares worth of $1,593,840 in a transaction dated June 9, 2016. In this transaction, 24,000 shares were sold at $66.41 per share.
Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic, scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services, such as phase research, market access and consulting, and health information analytics and technology consulting.